# Safety, Tolerability and Blood Sampling of GSK3923868 Administered Via Dry Powder Inhaler to Healthy Participants of Chinese, Japanese and European Ancestry

> **NCT06577597** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 30 (actual)

## Conditions studied

- Respiratory Tract Infections

## Interventions

- **DRUG:** GSK3923868
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06577597
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-02
- **Primary completion:** 2024-11-01
- **Final completion:** 2024-11-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06577597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06577597, "Safety, Tolerability and Blood Sampling of GSK3923868 Administered Via Dry Powder Inhaler to Healthy Participants of Chinese, Japanese and European Ancestry". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06577597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*